Overview

Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure

Status:
Completed

Trial end date:
2018-04-24

Target enrollment:

Participant gender:

Summary

The dose for intravenous administration of OPC-61815 achieving tolvaptan exposure equivalent to that for oral administration of tolvaptan 15-mg tablet will be investigated by administering OPC-61815 injection 2 to 16mg or tolvaptan 15-mg oral tablet to subjects with congestive heart failure.

Phase:

N/A

Details

Lead Sponsor:

Otsuka Pharmaceutical Co., Ltd.

Treatments:

Tolvaptan